An exploratory approach to the serotonergic hypothesis of depression: Bridging the synaptic gap

Medical Hypotheses

Volumn 56, Issue 2, 2001, Pages 235-243

  Dursun, S M ^a   Blackburn, J R ^a   Kutcher, S P ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DEPRESSION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE; SYNAPTIC TRANSMISSION;

EID: 0035091437     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1187     Document Type: Article

References (75)

1. Norepinephrine in depressive reactions: A review
2. Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter
3. Relapse of depression after rapid depletion of tryptophan
4. The pharmacologic treatment of depression
5. Treatment of acute depression
6. Serotonin receptor subtypes in depression: Evidence from studies in neuroendocrine regulation
7. Serotonin depression: A biological subgroup within the affective disorders?
8. CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide
9. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers
10. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients
11. Tryptophan depletion causes a rapid lowering of mood in normal males
12. Differences between males and females in rates of serotonin synthesis in human brain
13. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan
14. Tryptophan deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients
15. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse
16. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans
17. The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder
18. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy
19. Monoamines and the mechanisms of action: Effects of catecholamine depletions on mood of patients treated with antidepressants
20. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males
21. Acute tryptophan depletion blocks morphine analgesia in the cold-presser test in humans
22. The effect of tryptophan depletion and enhancement on subjective and behavioral aggression in normal male subjects
23. Lack of behavioral effects of monoamine depletion in healthy subjects
24. Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: A pilot study
25. Mood response acute tryptophan depletion in healthy volunteers: Sex differences and temporal stability
26. Mood lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders
27. 5-Hydroxytryptamine receptor subtypes: Molecular and functional diversity
28. Serotonin receptors: Subtypes, functional responses and therapeutic relevance
29. 2 binding site in rat cerebral cortex but not in subcortical regions
30. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims
31. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects
32. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates
33. Interactions between 5-hydroxytryptamine receptor subtypes: Is disturbed receptor balance contributing to the symptomatology of depression in humans?
34. Advances in psychopharmacology: Mood disorders and dementia
35. Antidepressants and serotonergic neurotransmission: An integrative review
36. Lithium and myoinositol homeostasis
37. On the functions of lithium: The mood stabilizer
38. The effect of lithium and other agents on the activity of myo-inositol-1-phosphatase from bovine brain
39. Neural and developmental actions of lithium: A unifying hypothesis
40. Inositol monophosphatase - A putative target for Li+ in the treatment of bipolar disorder
41. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression
42. Lithium and the brain: A psychopharmacological strategy to a molecular basis for manic depressive illness
43. Phosphoinositide signaling in human brain
44. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium
45. How does lithium work on manǐc depression? Clinical and psychological correlates of the inositol theory
46. The effect of peripheral inositol injection on rat motor activity models of depression
47. Restoration of brain myo-inositol levels increases latency to lithium-pilocarpine seizures
48. Lithium treatment and prophyaxis in unipolar depression: A meta-analysis
49. Platelet phosphoinositide signaling system: An overstimulated pathway in depression
50. Mechanism of inositol monophosphatase, the putative target of lithium therapy
51. Reduced myo-inositol I cerebrospinal fluid from patients with affective disorders
52. CSF inositol does not predict antidepressant response to inositol
53. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain
54. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain
55. Protein kinase C in the postmortem brain of teenage suicide victims
56. Increased sensitivity of the inositol phospholipid system in neutrophils from patients with acute major depressive episodes
57. Platelet imidazoline receptors and regulatory G proteins in patients with major depression
58. Inositol treatment raises CSF inositol levels
59. Inositol 6 gm daily may be effective in depression but not in schizophrenia
60. Double-blind, controlled trial of inositol treatment of depression
61. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder
62. Inositol treatment of obsessive compulsive disorder
63. The effect of inositol on lithium-induced polyuria-polydipsia in rats and humans
64. Inositol treatment of Alzheimer's disease
65. CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia
66. Controlled trials of inositol in psychiatry
67. Inositol treatment of autism
68. Inositol may worsen attention deficit disorder with hyperactivity
69. High-dose dietary myo-inositol supplementation does not alter the ischaemia phenomenon in human diabetics
70. The mechanism of muscarinic receptor-stimulated phosphatidylinositol resynthesis in 1321N1 astrocytoma cells and its inhibition by Li+
71. Modulation of protein kinase C isozymes and substrates by lithium: The role of myo-inositol
72. 1Areceptor agonists in the mouse